CytoDyn

Two good friends recently saved by monoclonal antibody treatment. Unvaccinated friend with multiple sclerosis lucky to get REGEN-COV in nick of time. Fully vaccinated ER Doc friend dying in ICU got "Leronlimab" (compassionate use) and got better in 24hrs - now out of hospital ❤️

$CYDY CytoDyn granted US patent for methods of treating coronavirus infection with leronlimab tinyurl.com/ygyd2tyu @CytoDyn #CYDY

$CYDY CytoDyn's flagship drug leronlimab included in Nature Communications' study on HIV prevention tinyurl.com/yy4gvb6n @CytoDyn #CYDY

$CYDY CytoDyn receives order from Chiral Pharma to use Vyrologix on COVID-19 patients in the Philippines tinyurl.com/yxu5lqtd @CytoDyn #CYDY

$CYDY CytoDyn forms supply and distribution deal with Indian firm for leronlimb as coronavirus treatment tinyurl.com/y8osg43p @CytoDyn #CYDY

$CYDY CytoDyn CEO talks through recent $50M convertible debt financings efforts tinyurl.com/ye7p59ks @CytoDyn #CYDY

$CYDY CytoDyn updates investors on the status of its coronavirus and NASH-focused clinical trials tinyurl.com/yygzg3jr @CytoDyn #CYDY

$CYDY CytoDyn provide update on their path to approval for treatment of COVID-19 tinyurl.com/y3m3snqv via @proactive_NA @CytoDyn #CYDY @OTCMarkets #OTCQB

What if COVID-19 was just a bad cold? An underdog Covid-19 therapeutic called Leronlimab, following statistically significant trial results, is set to change the course of the pandemic. $cydy $gild #leronlimab $rlftf #68458a876234" target="_blank" rel="nofollow noopener">forbes.com/sites/thomasla…

$CYDY CytoDyn reveals latest mild-to-moderate coronavirus patient data in Phase 2 trial tinyurl.com/y58yqhbc via @proactive_NA @CytoDyn #CYDY @OTCMarkets #OTCQB

$CYDY CytoDyn to submit request for pre-submission meetings in U.K. for Leronlimab tinyurl.com/yyb7vv8n via @proactive_NA @CytoDyn #CYDY @OTCMarkets #OTCQB

$CYDY CytoDyn’s Leronlimab receives positive DSMC recommendation in ongoing Phase 3 study tinyurl.com/y2xosogz via @proactive_NA @CytoDyn #CYDY @OTCMarkets #OTCQB

$CYDY CytoDyn addresses negative claims made by healthcare publication STAT on its coronavirus study tinyurl.com/y5k2f5o9 via @proactive_NA @CytoDyn #CYDY @OTCMarkets #OTCQB

$CYDY CytoDyn showcases its patient safety data from its Phase 2 coronavirus trial tinyurl.com/y3kjse8k via @proactive_NA @CytoDyn #CYDY @OTCMarkets #OTCQB

$CYDY CytoDyn files to uplist to the Nasdaq, updates on coronavirus trials tinyurl.com/yy5zxnan via @proactive_NA @CytoDyn #CYDY @OTCMarkets #OTCQB

Exciting news. I will have the CEO of CytoDyn as a guest to discuss Leronlimab with #koolbeens on this Saturday.

$CYDY CytoDyn CEO calls Citron Research report 'false', updates on coronavirus clinical trials tinyurl.com/ycqwgfo3 via @proactive_NA @CytoDyn #CYDY @OTCMarkets #OTCQB

$CYDY - Don't Forget Cytodyn's Other Prospects. seekingalpha.com/article/435569… #stocks #markets #economy

What is leronlimab? Learn more about Dr. Harish Seethramraju’s research on the drug as a potential treatment for #COVID19 via @thisisthebronx: bit.ly/319qIh1 #HealthcareHeroes

#cytokinestorms have inflamed & damaged the organs of many #COVID19 patients. In two separate trials, Montefiore & @EinsteinMed were the first site to investigate anti-inflammatory drug leronlimab’s ability to prevent these storms: bit.ly/2XnP9ns